Core Viewpoint - SeaStar Medical Holding Corporation announced a 1-for-10 reverse stock split effective January 5, 2026, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 10 pre-split shares into 1 post-split share, with stockholders receiving whole shares in lieu of any fractional shares [2]. - The reverse split will proportionately reduce the number of shares issuable upon the exercise of outstanding stock options and warrants, while also increasing their exercise prices accordingly [2]. Group 2: Stockholder Information - Stockholders will receive information regarding their share ownership from Continental Stock Transfer and Trust Company following the reverse stock split [3]. - Those holding shares through banks or brokers will have their positions automatically adjusted without needing further action [3]. Group 3: Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first commercial product, QUELIMMUNE (SCD-PED) therapy, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [5]. - The company is conducting the NEUTRALIZE-AKI pivotal trial for its SCD therapy in adult patients, addressing a significant unmet medical need affecting over 200,000 adults in the U.S. annually [5].

Company Overview - AbbVie Inc. is ranked sixth among prominent biomedical companies by revenue and has shifted focus from blockbuster drug revenues to growing oncology and neuroscience segments [1] - The company is recognized as a top healthcare stock pick across Wall Street and offers a reliable 2.93% dividend [1] Product Portfolio - AbbVie develops and manufactures a range of pharmaceuticals, including Imbruvica for blood cancers, Rinvoq for various autoimmune diseases, Skyrizi for psoriasis, and Humira for autoimmune and intestinal diseases [1] - The company also provides a variety of eye care products, including Ozurdex and Restasis, as well as treatments for advanced Parkinson's disease and migraine [7][9] Financial Performance - Quality dividend stocks, such as those offered by AbbVie, are favored by investors for their steady income and potential for total return, which includes interest, capital gains, and dividends [2][4] - Companies with strong dividend growth histories, like AbbVie, can provide consistent income even during economic fluctuations [4] Market Position - AbbVie is noted for its sustainable payout ratios and consistent free cash flow generation, making it a solid choice for long-term investors [4] - The company is part of a broader trend where quality dividend stocks are expected to perform well in the coming years, particularly as inflation rates decline [5][6]

Company Overview - iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital health company specializing in wearable biosensors and cloud-based analytics for cardiac monitoring, integrating AI into arrhythmia detection and predictive diagnostics [4] Industry Outlook - Morgan Stanley raised its price target on iRhythm Technologies from $195 to $205, maintaining an Overweight rating, reflecting a positive outlook for the MedTech industry heading into 2026 [1] - The MedTech industry is seen as well-positioned due to major product cycles, a supportive hospital spending environment, and current valuations at trough levels [1] Recent Developments - On November 21, iRhythm presented new data at the joint Asia Pacific Heart Rhythm Society and Japan Heart Rhythm Society scientific sessions, showcasing a large-scale retrospective analysis of its Zio long-term continuous ECG monitoring (LTCM) system [2] - The study involved data from 408,470 US patients using the Zio LTCM service for up to 14 days, demonstrating consistent performance in Asian patients compared to non-Asian patients, despite lower baseline prevalence of conditions like atrial fibrillation, heart failure, and coronary artery disease [3] - Detection rates and repeat monitoring rates were similar across diverse populations, supporting the generalizability of Zio monitoring [3]

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as a leading healthcare AI stock, with Citi adjusting its price target from $455 to $420 while maintaining a Buy rating [1][2] - The company declared a quarterly dividend of $0.88 per share, which is a 4.8% increase from the previous dividend paid in October 2025, resulting in an annualized dividend of $3.52 per share [2] - Stryker appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026, who will oversee global businesses and corporate strategy [3] - Dylan Crotty will be promoted to Group President of Orthopaedics, succeeding Stiles, and is noted for his operational leadership [4] Group 2 - Stryker designs and manufactures medical technologies in orthopedics, surgical equipment, and neurotechnology, utilizing AI in surgical robotics, predictive analytics, enhanced imaging, inventory management, and remote monitoring [5]

Funding a med-tech company isn’t for VCs who want quick returns.Gabriel Sanchez, co-founder of @enspectra, joins us on Build Mode to talk about how you keep a company afloat when it could be 10 years before your product is able to hit the market.Listen to the full episode here: https://t.co/i6TUbAZCki ...

Group 1 - Insulet Corporation (NASDAQ:PODD) is recognized as one of the best growth stocks to buy in 2026, with a recent price target adjustment by Truist from $412 to $390 while maintaining a Buy rating [1] - Canaccord raised Insulet's price target to $450 from $432, reaffirming a bullish outlook on the MedTech sector for 2026, driven by consistent demand from an aging demographic and a robust M&A environment [2] - Evercore ISI initiated coverage of Insulet with an Outperform rating and a price target of $370, highlighting the company's unique tubeless design as a key factor in revolutionizing the insulin pump market [3] Group 2 - Truist expressed a more positive outlook on the healthcare sector for 2026, citing increasingly attractive relative valuations, but cautioned that the sector may serve as a source of funds rather than a primary destination for new capital [1] - Canaccord emphasized that Insulet is well-positioned for a multi-year cycle of outperformance due to recent label expansion and the rollout of Automated Insulin Delivery systems for Type 2 diabetes patients [2] - The overall sentiment in the MedTech sector is optimistic, with expectations of heightened focus on acute healthcare requirements and an increasing openness to new IPOs [2]

Core Viewpoint - Optum Behavioral Health has expanded its medical policy to cover Deep TMS therapy for adolescents aged 15 and older with major depressive disorder, reflecting a growing recognition of this treatment as essential in modern mental health care [1][2]. Group 1: Coverage Expansion - Optum's policy expansion aligns with other insurers such as Evernorth Health Services, CVS/Aetna, and several Blue Cross and Blue Shield companies, collectively covering approximately 180 million lives [2]. - The inclusion of adolescents in the coverage for Deep TMS therapy signifies a commitment to early intervention and innovation in treating major depressive disorder [2]. Group 2: Public Health Challenge - An estimated 5 million adolescents aged 15–21 in the U.S. experience major depression, which disrupts developmental milestones and can lead to higher healthcare costs and comorbid conditions [3]. - The limited treatment options for adolescents who cannot tolerate or do not respond to medication highlight a critical gap in access to effective treatments for this vulnerable population [3]. Group 3: Deep TMS Technology - BrainsWay's Deep TMS is FDA cleared as an adjunct therapy for adolescents with depression, demonstrating meaningful response and remission rates [4]. - The company utilizes proprietary H-coil technology and is committed to expanding access to advanced neurostimulation therapies through ongoing clinical research and collaboration with providers [4][5]. Group 4: Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5]. - The company was founded in 2003 and operates in the U.S. and Israel, focusing on increasing global awareness and access to Deep TMS technology [5].

Core Viewpoint - The company, Yahua Electronics, is focusing on the integration of its smart communication systems for hospital wards with brain-computer interface (BCI) technology, aiming to innovate in medical and care scenarios through technological advancements [1] Group 1: Company Developments - Yahua Electronics has announced its smart communication interactive system for hospital wards can achieve preliminary integration with brain-computer interface (BCI) technology [1] - The company is dedicated to the research and development of smart communication systems in hospitals, emphasizing the application of new technologies such as BCI, IoT, and AI in medical and care environments [1]

Funding a med-tech company isn’t for VCs who want quick returns.Gabriel Sanchez, co-founder of @enspectra, joins us on Build Mode to talk about how you keep a company afloat when it could be 10 years before your product is able to hit the market.Listen to the full episode here: https://t.co/i6TUbAZCki ...

Core Insights - Companies like Brookfield Renewable, Realty Income, and Medtronic are expected to continue increasing their dividends in 2026, supported by strong financial performance and growth strategies [1][16]. Brookfield Renewable - Brookfield Renewable currently has a dividend yield of 4% and has increased its dividend by at least 5% annually for the past 14 years, with expectations of 5% to 9% growth in the coming years [4][7]. - The company benefits from a stable cash flow generated by long-term fixed-rate contracts with inflation-linked rate escalations, which supports its dividend growth [5]. - Brookfield has a robust pipeline of development projects and acquisitions, aiming for over 10% annual growth in funds from operations (FFO) [7]. Realty Income - Realty Income offers a monthly dividend with a current yield of 5.7% and has a strong history of increasing its payout, having raised it 133 times since 1994, including 113 consecutive quarters [8][10]. - The REIT maintains a conservative dividend payout ratio of around 75% of adjusted FFO, generating approximately $850 million in free cash flow annually for reinvestment [10]. - Realty Income has diversified its investment platform, with significant investments in Europe due to higher initial cash yields, and continues to find attractive opportunities to support future dividend increases [11]. Medtronic - Medtronic has a dividend yield of 2.9% and has increased its dividend for 48 consecutive years, demonstrating a strong commitment to returning value to shareholders [12][14]. - The company generated $7 billion in cash from operations and $5.2 billion in free cash flow in the last fiscal year, returning $6.3 billion to shareholders through dividends and stock repurchases [14]. - Despite facing some headwinds that may slow earnings-per-share growth to around 1% this fiscal year, Medtronic anticipates high-single-digit growth in fiscal 2027 as these challenges subside [15].